Tag: ASCO 2023

New treatment option for myeloma

CAR-T cell treatments are now routinely used in some blood cancers.

A recent study presented at the American Society of Clinical Oncology, shows that CAR-T cell treatment is a valuable option for those patients who have already tried conventional treatments .

References

1. Daily Mail. Breakthrough in treating one of the deadliest blood cancers: ‘Remarkably effective’ new immunotherapy can slow disease’s progress by 74%

2. ASCO 2023: Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.

3. ASCO 2023: First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.

New radiotherpy alternative treatment for low grade brain tumours

Brain Radiation therapy has long term side effects particularly in young people

People with low grade cancer of brain have a prognosis of many years.

Hence, it is important from a quality of life point of view that alternative treatments are used to minimise or avoid the risk of brain damage from radiation

Vorasidenib is a new type of medical treatment . It is a tablet developed specifically to target a specific vulnerable part of low grade brain cancers. The Vorasidenib tablets target abnormal proteins in cancer and hence spares a lot of normal tissues.

A study presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 4 is very promising.

Preliminary results show that the tablet significantly delays the growth of the tumour.

References

1. National Cancer Institute. Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas.

2. NEJM. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

3. Vorasidenib ASCO2023 news. INDIGO: Vorasidenib Offers Patients With IDH-Mutant Low-Grade Glioma a Means to Delay Chemotherapy and Radiotherapy

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.